Torrent Pharmaceuticals share price
NSE: TORNTPHARMBSE: 500420Pharmaceuticals & BiotechnologyLarge Cap
Torrent Pharmaceuticals Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1994 on BSE, Nov 2002 on NSE
Last close ₹4,613.40up ₹33.40 (0.73%)BSE ₹4,635.15
Share price at the NSE close on 30 Oct 2026. Previous close ₹4,580.00.
30 Oct: open ₹4,560.00, high ₹4,672.00, low ₹4,532.00
52-week range of traded prices to 30 Oct 2026
₹3,532.60Low, 6 Nov 2025₹5,250.00High, 3 Aug 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,75,479 Cr61st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 82.62
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 9.55
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.82%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 15.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.76
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 4,36,645
About Torrent Pharmaceuticals
Torrent Pharmaceuticals develops, makes and sells medicines, with a focus on long-term (chronic) conditions such as heart, nervous system, diabetes and digestive disorders.12 It sells branded generics, its own brands of medicines whose patents have expired, in India, its largest market, and in Brazil.13 It also sells generics, copies of medicines supplied after their patents expire, in regulated markets led by the United States and Germany.14
It operates in more than 50 countries, including markets in Asia Pacific, Africa, the Middle East and Latin America.5 Its research and development centre is in Gujarat.6 It sells through wholesale distributors, stockists, retail and e-commerce partners, and to hospitals, clinics and government institutions.7
The business began in 1959 as Trinity Laboratories under its founder, U. N. Mehta.8 It was incorporated in 1972.9 It entered Germany in 2005 by buying Heumann Pharma from the Pfizer group.10 In India it has added brands by buying businesses from Elder Pharmaceuticals and Unichem and by acquiring Curatio Health Care.11
The company belongs to the Torrent Group, which also works in power, gas and electricity distribution, and its holding company is Torrent Investments Limited.1213 Samir Mehta, chairman of the Torrent Group, is its Executive Chairman and a promoter; his son Aman Mehta is Managing Director.1415
Torrent Pharmaceuticals key points
Results
- Including JB Pharma, consolidated revenue was ₹4,921 crore in the quarter to Jun 2026, up 55%, and operating EBITDA (earnings before interest, tax, depreciation and amortisation) was ₹1,664 crore, up 61%, a margin of 33.8%.16
- In the year to Mar 2026, consolidated revenue was ₹13,980 crore, up 21% from ₹11,516 crore, and operating EBITDA was ₹4,559 crore against ₹3,721 crore.17
- Consolidated profit after tax was ₹2,138 crore in the year to Mar 2026, against ₹1,911 crore a year earlier.18
- Without JB Pharma, the company's revenue grew 17% and its operating EBITDA was ₹1,240 crore, up 20%, in the quarter to Jun 2026; in the year to Mar 2026 they grew 15% and 16%.1920
Market position
- Combined with JB Pharma, it ranked 5th in the Indian pharmaceutical market in the year to Mar 2026, up from 7th, and 4th by doctors' prescriptions, up from 10th.2122
- Combined with JB Pharma, it ranked 1st in heart (cardiac) medicines in India in Mar 2026, 3rd in central nervous system (CNS) and gastrointestinal medicines, and 5th in pain management and dermatology.23
- Its semaglutide brands (a diabetes and weight-loss medicine) held 36% of the Indian market for the oral and injectable forms combined in the quarter to Jun 2026.24
- In Brazil it ranks 1st among Indian drug makers by value; in Germany, 1st among them and 5th in the generics market, where it held 4.9% in the year to Mar 2026.2526
Revenue mix
Where revenue comes from
- The India base business, without JB Pharma, contributed 54% of revenue in the year to Mar 2026.30
- India revenue excluding JB Pharma was ₹2,157 crore in the quarter to Jun 2026, up 19% against 12% for the Indian market.31
- US sales were $151 million in the year to Mar 2026, 12th among Indian generic companies there; in the quarter to Jun 2026, US revenue was $44 million, up 23% in constant currency, partly from one-time opportunities, the company said.3233
- Brazil revenue was BRL 817 million in the year to Mar 2026, up 12% in constant currency; Germany revenue was €29 million in the quarter to Jun 2026, down 9% in constant currency.3435
Plants and capacity
- Excluding JB Pharma, it has 8 manufacturing units in India, with capacity for 85 MT of active pharmaceutical ingredients (APIs, the active substance in a medicine) and more than 2,500 crore doses, used at 60%.3637
- Its Dahej and Vizag plants received Establishment Inspection Reports (issued when an inspection is closed) from the US Food and Drug Administration, and all 4 plants supplying the US market comply with its requirements.38
Research and development
- R&D spending was ₹650 crore in the year to Mar 2026, about 5% of the company's total revenue, with more than 900 scientists at a single R&D centre serving all markets.394041
- In the US it holds 124 ANDA approvals (abbreviated new drug applications, the licence to sell a generic), including 3 tentative, with 16 pending and 21 products in development.42
- It received market authorisation from India's drug regulator (CDSCO/DCGI) for brexpiprazole tablets, for nervous system disorders, and for an oral form of semaglutide, for metabolic disorders.43
What the company expects
- On its earnings call of 30 Jul 2026, the company said double-digit revenue growth for JB Pharma's Indian prescription business should still be possible in the year to Mar 2027.44
- On its earnings call of 30 Jul 2026, the company said it expects its US business to be profitable in the year to Mar 2027, unlike the previous 5 years.45
- On its earnings call of 30 Jul 2026, the company said net debt (borrowings less cash) stood at 2.07 times underlying EBITDA of the combined company, and it would not want to exceed about 3 to 3.5 times for any opportunity.4647
- The company stated in its annual report for the year to Mar 2026 that it aims to pay out 50% of annual consolidated profit after tax, before non-cash acquisition charges, as dividend; that year's dividend was ₹38 a share.48
Recent events
- On 7 Oct 2026, India Ratings and Research affirmed its credit rating (a measure of ability to repay debt) at IND AA+ and raised the outlook from stable to positive.49
- J.B. Chemicals & Pharmaceuticals (JB Pharma) merged into the company with effect from 8 Jul 2026, counted from 21 Jan 2026; JB Pharma's shareholders receive 51 company shares for every 100 JB Pharma shares.5051
Last updated
All 51 sources, each with its page
- 1. Annual report, 1 Jun 2026, page 7
- 2. Annual report, 1 Jun 2026, page 22
- 3. Annual report, 1 Jun 2026, page 9
- 4. Annual report, 1 Jun 2026, page 54
- 5. Annual report, 1 Jun 2026, page 9
- 6. Annual report, 1 Jun 2026, page 133
- 7. Annual report, 1 Jun 2026, page 85
- 8. Annual report, 1 Jun 2026, page 7
- 9. Annual report, 1 Jun 2026, page 226
- 10. Annual report, 1 Jun 2026, page 13
- 11. Annual report, 1 Jun 2026, page 8
- 12. Annual report, 1 Jun 2026, page 6
- 13. Annual report, 1 Jun 2026, page 60
- 14. Annual report, 1 Jun 2026, page 113
- 15. Annual report, 1 Jun 2026, page 223
- 16. Earnings call, 30 Jul 2026, page 2
- 17. Annual report, 1 Jun 2026, page 14
- 18. Annual report, 1 Jun 2026, page 14
- 19. Earnings call, 30 Jul 2026, page 2
- 20. Annual report, 1 Jun 2026, page 55
- 21. Annual report, 1 Jun 2026, page 54
- 22. Annual report, 1 Jun 2026, page 15
- 23. Annual report, 1 Jun 2026, page 10
- 24. Earnings call, 30 Jul 2026, page 3
- 25. Annual report, 1 Jun 2026, page 80
- 26. Annual report, 1 Jun 2026, page 54
- 27. Annual report, 1 Jun 2026, page 54
- 28. Annual report, 1 Jun 2026, page 79
- 29. Annual report, 1 Jun 2026, page 79
- 30. Annual report, 1 Jun 2026, page 78
- 31. Earnings call, 30 Jul 2026, page 3
- 32. Annual report, 1 Jun 2026, page 80
- 33. Earnings call, 30 Jul 2026, page 4
- 34. Annual report, 1 Jun 2026, page 80
- 35. Earnings call, 30 Jul 2026, page 4
- 36. Annual report, 1 Jun 2026, page 17
- 37. Annual report, 1 Jun 2026, page 26
- 38. Annual report, 1 Jun 2026, page 15
- 39. Annual report, 1 Jun 2026, page 17
- 40. Annual report, 1 Jun 2026, page 81
- 41. Annual report, 1 Jun 2026, page 30
- 42. Annual report, 1 Jun 2026, page 80
- 43. Annual report, 1 Jun 2026, page 32
- 44. Earnings call, 30 Jul 2026, page 3
- 45. Earnings call, 30 Jul 2026, page 11
- 46. Earnings call, 30 Jul 2026, page 2
- 47. Earnings call, 30 Jul 2026, page 12
- 48. Annual report, 1 Jun 2026, page 55
- 49. Exchange filing, 7 Oct 2026, page 1
- 50. Earnings call, 30 Jul 2026, page 2
- 51. Annual report, 1 Jun 2026, page 60
Results
Consolidated; ₹ crore.Torrent Pharmaceuticals quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +42.1%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −0.7%
Quarter to Sep 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹4,979 Crup 1.18%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹534 Crdown 5.65%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 10.7%
Revenue by quarter
Peak revenue ₹4,979 Cr, quarter to Sep 2026; lowest ₹2,809 Cr, quarter to Dec 2024
Net profit by quarter, a loss in red
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,809 | 2,959 | 3,178 | 3,302 | 3,303 | 4,197 | 4,921 | 4,979 |
| Net profit | 503 | 498 | 548 | 591 | 635 | 364 | 566 | 534 |
| Net margin | 17.9% | 16.8% | 17.2% | 17.9% | 19.2% | 8.7% | 11.5% | 10.7% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹13,980 Crup 21.40%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹2,138 Crup 11.88%
- Net margin
- 15.3%
Revenue by year
Peak revenue ₹13,980 Cr, year to Mar 2026; lowest ₹5,857 Cr, year to Mar 2017
Net profit by year, a loss in red
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5,857 | 6,002 | 7,673 | 7,939 | 8,005 | 8,508 | 9,620 | 10,728 | 11,516 | 13,980 |
| Net profit | 934 | 678 | 436 | 1,025 | 1,252 | 777 | 1,245 | 1,656 | 1,911 | 2,138 |
| Net margin | 15.9% | 11.3% | 5.7% | 12.9% | 15.6% | 9.1% | 12.9% | 15.4% | 16.6% | 15.3% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Generic Formulation Business, which carries all its revenue.
Valuation
Today, against the company's own history.Torrent Pharmaceuticals PE ratio and valuation
Price to earnings
At or below today's level on 98% of 2,479 trading days over the last 10 years.
LowestHighest
Its median40.97Industry median27.53
Price to book
At or below today's level on 57% of 1,913 trading days since Nov 2018.
LowestHighest
Its median8.92Industry median2.88
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 22% of 2,478 trading days over the last 10 years.
LowestHighest
Its median0.98%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +31.6% | +13.2% | +15.5% | 0.9% |
| 3 years | +41.0% | +20.2% | +16.5% | 1.0% |
| 5 years | +28.2% | +11.6% | +13.9% | 1.1% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual fund holdings
383 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 148 of the 208 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 3 more funds filed their first portfolio on record, holding it.All 383 funds holding Torrent Pharmaceuticals
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 12
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 131
- CutCut. Funds that held fewer shares than at the end of the month before.
- 77
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 158
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 7
| Fund | |||
|---|---|---|---|
 HDFC Large Cap FundHDFC Mutual Fund | 31,80,904 | 4.09% | ₹1,526.8 Cr |
 Kotak Mid Cap FundKotak Mahindra Mutual Fund | 17,30,170 | 1.25% | ₹830.5 Cr |
 Axis Small Cap FundAxis Mutual Fund | 14,80,612 | 2.32% | ₹710.7 Cr |
| Kotak Arbitrage FundKotak Mahindra Mutual Fund | 9,90,000 | 0.63% | ₹475.2 Cr |
| Axis Large Cap FundAxis Mutual Fund | 7,82,853 | 1.29% | ₹375.8 Cr |
 UTI Flexi Cap FundUTI Mutual Fund | 6,78,700 | 1.45% | ₹325.8 Cr |
 Franklin India Large Cap FundFranklin Templeton Mutual Fund | 5,90,223 | 4.10% | ₹283.3 Cr |
 ICICI Prudential Nifty Next 50 Index FundICICI Prudential Mutual Fund | 5,86,946 | 2.89% | ₹281.7 Cr |
 SBI Healthcare Opportunities FundSBI Mutual Fund | 5,40,000 | 4.42% | ₹259.2 Cr |
| ICICI Prudential Balanced Advantage FundICICI Prudential Mutual Fund | 5,36,860 | 0.36% | ₹257.7 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 30 Oct 2025.Torrent Pharmaceuticals insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Others2 purchases, 0 sales₹0.12 CrNo saleNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.₹0.12 Cr
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Torrent Pharmaceuticals competitors and peers
Pharmaceuticals, 215 listed companies, priced on 30 Oct 2026. The table lists the 8 companies closest to Torrent Pharmaceuticals in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical IndustriesSUNPHARMA | 4,26,530 | 35.26 | 5.10 | +11.4% | +16.6% | 15.5% | 16.9% | 0.90% |
 Divi's LaboratoriesDIVISLAB | 2,59,628 | 88.76 | 15.49 | +16.3% | +26.8% | 18.4% | 20.8% | 0.31% |
 Laurus LabsLAURUSLABS | 1,29,972 | 97.00 | 21.45 | +23.0% | +95.9% | 24.7% | 21.8% | 0.08% |
 Zydus LifesciencesZYDUSLIFE | 1,24,239 | 27.53 | 4.58 | +21.1% | −1.3% | 17.7% | 15.9% | 0.08% |
 Dr. Reddy's LaboratoriesDRREDDY | 1,12,849 | 40.30 | 2.91 | −3.5% | −51.5% | 7.5% | 6.0% | 0.59% |
 CiplaCIPLA | 1,11,397 | 38.45 | 3.15 | −0.7% | −46.8% | 8.5% | 9.7% | 0.94% |
 Mankind PharmaMANKIND | 1,02,964 | 45.79 | 5.86 | +13.3% | +28.4% | 13.7% | 13.6% | 0.00% |
 Aurobindo PharmaAUROPHARMA | 96,744 | 26.06 | 2.55 | +9.1% | +9.5% | 10.5% | 11.5% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Torrent Pharmaceuticals dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹38.00 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 29 May 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹9.00 |
| 18 Feb 2026 | Interim | ₹29.00 |
| 20 Jun 2025 | Final | ₹6.00 |
| 31 Jan 2025 | Interim | ₹26.00 |
| 21 Jun 2024 | Final | ₹6.00 |
| 12 Feb 2024 | Interim | ₹22.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Torrent Pharmaceuticals announcements
Oct 2026
23 Oct · Results
16 Oct · Management
Torrent Pharmaceuticals share price by year
Each calendar year to 2025.Torrent Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 3,850.00 | +14.6% | 3,850.00 | 2,930.30 |
| 2024 | 3,360.05 | +45.7% | 3,557.25 | 2,296.30 |
| 2023 | 2,305.55 | +48.7% | 2,305.55 | 1,459.85 |
| 2022 | 1,550.60 | −5.4% | 1,694.30 | 1,252.20 |
| 2021 | 1,639.23 | +17.0% | 1,639.23 | 1,183.38 |
| 2020 | 1,401.35 | +51.6% | 1,505.40 | 886.05 |
| 2019 | 924.53 | +4.4% | 974.88 | 733.90 |
| 2018 | 885.70 | +24.9% | 917.45 | 619.35 |
| 2017 | 709.28 | +7.7% | 776.30 | 582.78 |
| 2016 | 658.58 | −9.3% | 850.50 | 613.50 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 29 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 29 Oct 2026 | 4,540.00 | 4,610.90 | 4,525.30 | 4,580.00 | 4,573.40 | 3,20,055 | 63.1% |
| 28 Oct 2026 | 4,597.10 | 4,597.10 | 4,486.60 | 4,557.00 | 4,551.06 | 2,26,215 | 57.8% |
| 27 Oct 2026 | 4,547.90 | 4,649.90 | 4,547.80 | 4,625.00 | 4,610.10 | 3,19,590 | 65.3% |
| 26 Oct 2026 | 4,561.10 | 4,626.60 | 4,466.80 | 4,550.00 | 4,544.19 | 6,58,324 | 46.2% |
| 23 Oct 2026 | 4,637.90 | 4,650.70 | 4,476.10 | 4,524.40 | 4,522.19 | 3,28,595 | 57.1% |
| 22 Oct 2026 | 4,510.60 | 4,649.60 | 4,500.30 | 4,615.30 | 4,596.15 | 2,07,984 | 48.3% |
| 21 Oct 2026 | 4,560.00 | 4,572.90 | 4,470.40 | 4,553.80 | 4,519.37 | 2,84,392 | 65.3% |
| 19 Oct 2026 | 4,551.20 | 4,618.70 | 4,532.40 | 4,558.70 | 4,566.03 | 2,50,305 | 58.6% |
| 16 Oct 2026 | 4,584.10 | 4,618.90 | 4,550.40 | 4,558.90 | 4,573.82 | 2,11,036 | 62.7% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 8 Jul 2022 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
| 23 Jul 2013 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- TORNTPHARM
- BSE code
- 500420
- ISIN
- INE685A01028
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.torrentpharma.com
- CIN
- L24230GJ1972PLC002126
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1972
- Registered office
- Torrent House, Off Ashram Road, Ahmedabad 380009, Gujarat
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty Next 50, Nifty 100, Nifty 200, BSE 200, Nifty 500, BSE 500